- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | Forum Residential Coaching (FRC) for UPSC preparation Click Here to know more →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 10th Oct. Click Here to Read More →
Source: The post is based on the article “World’s first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above” published in PIB on 2nd December 2022.
What is the News?
World’s first intra-nasal vaccine for COVID named “iNCOVACC” has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above.
What is iNCOVAC Vaccine?
iNCOVAC (BBV154) is the World’s first intra-nasal vaccine.
Developed by: Bharat Biotech International Limited (BBIL)
The product development and Clinical trials of the vaccine were funded by the Department of biotechnology and BIRAC under the Mission COVID Suraksha Program.
Click here to read more about the vaccine
What are the other decisions taken by the Government?
Formation of Biotechnology Research and Innovation Council(BRIC)
BRIC will be an apex autonomous body of the Department of Biotechnology(DBT). It has been formed by subsuming 14 Autonomous Institutions of DBT.
Aim: To achieve centralized and unified governance to maximize the impact of biotech research.
